论文部分内容阅读
近十年来,人们对 ZES 的认识取得了较大进展。发病机理方面,可以没有空腹血清胃泌素升高,肿瘤组织释放另一种非胃泌素促胃酸分泌物质。诊断方面,空腹血清胃泌素<1,000pg/ml 者,可行胰液素激发试验,常规方法不能定位的患者,可行经皮肝穿刺选择性门静脉插管取血作血清胃泌素测定。治疗方面,H_2受体阻断剂取代了以往的全胃切除术,但原发肿瘤切除和胃近端迷走神经切断仍不失为有效的治疗方法。
In the recent ten years, great progress has been made in understanding ZES. Pathogenesis, there may be no fasting serum gastrin, tumor tissue to release another non-gastrin gastric acid secretion substances. Diagnosis, the fasting serum gastrin <1,000 pg / ml, feasible pancreatic insulin provocation test, conventional methods can not be located in patients with percutaneous transhepatic cholangiocarcinoma can be selected for blood serum determination of serum gastrin. Treatment, H 2 receptor blockers replaced the previous total gastrectomy, but the primary tumor resection and proximal gastric vagotomy is still an effective treatment.